ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

INO vs RLYB // ENTERPRISE SCALE & MARKET CAP

Inovio Pharmaceuticals Inc. (NASDAQ) VS. Rallybio Corporation (NASDAQ) • 15-METRIC TALLY: INO 0 — RLYB 4
▲ ENTERPRISE SCALE & MARKET CAP LEADER: RLYB
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INO VS. RLYB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC INO RLYB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% 34.90% -99.90 RLYB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 4.13 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 RLYB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 27.1 40.4 -13.39 RLYB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $79.8M $83.0M -$3.2M RLYB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR INO REV RLYB REV INO GROSS % RLYB GROSS % INO FCF RLYB FCF
FY 2025 $65.3K $858.0K — — -$88.9M -$29.8M
FY 2024 $217.8K $636.0K — — -$104.6M -$49.3M
FY 2023 $832.0K $0 — — -$124.4M -$60.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INO // BETA —
RLYB // BETA —